Enumeral Biomedical, Pieris Pharmaceuticals deal

Enumeral granted Pieris exclusive, worldwide rights to IP related to its preclinical anti- PD-1 antibody program, ENUM 388D4, for development and commercialization of

Read the full 236 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE